Re: PMID: 10223406: Pramipexole - a new dopamine agonist for PD

[David and Sandra Norris <hishers@xxxxxxxx>]

Janet,

Does this new drug have the same results in patients that have been on
Sinemet for more than 11 years?

Thanks ,
Sandy

David and Sandy Norris

"Faith is the daring of the soul to go farther
than it can see."  William Newton Clarke
Sandy 38/dx'd for 11/had pd for 19yrs
----- Original Message -----
From: janet paterson <janet313@xxxxxxxxxxx>
To: <PARKINSN@xxxxxxxxxxxxxxxxxxxx>
Sent: Wednesday, May 05, 1999 7:27 AM
Subject: PMID: 10223406: Pramipexole - a new dopamine agonist for PD


> Pramipexole--a new dopamine agonist for the treatment of PD
>
> Although L-DOPA is the current 'gold standard' for treatment of
Parkinson's
> disease, its effectiveness fades rapidly [ed. note - 'huh?'] and its use
> results in serious motor fluctuations (on-off, wearing off, freezing,
> involuntary movements) for most patients with Parkinson's disease.
>
> Pramipexole is an aminothiazole dopamine agonist with selective actions at
> dopamine receptors belonging to the D2 subfamily, where it possesses full
> activity similar to dopamine itself.
>
> Pramipexole's preferential affinity for the D3 receptor subtype could
> contribute to efficacy in the treatment of both the motor and psychiatric
> symptoms of Parkinson's disease.
>
> Both in vitro and in vivo studies in animals suggest that pramipexole
> possesses numerous neuroprotective properties, including dopamine
> autoreceptor agonist properties, antioxidant properties, ability to block
> the mitochondrial permeability transition pore and the ability to
stimulate
> the release of trophic factors.
>
> Clinical studies have demonstrated that pramipexole has excellent
> pharmacokinetic properties and that it is an effective monotherapy in
> treating early Parkinson's disease and an effective adjunctive therapy
with
> L-DOPA in treating late Parkinson's disease.
>
> In addition, pramipexole has demonstrated efficacy in a clinical trial for
> the treatment of major depression.
>
> In the early disease studies, pramipexole was able to retard the need for
> L-DOPA treatment for several years.
>
> Thus, a new 'L-DOPA-sparing' paradigm for treating Parkinson's disease may
> now be possible, whereby patients are initially treated with pramipexole
> and L-DOPA is added only as necessary.
>
> J Neurol Sci 1999 Feb 1;163(1):25-31
> Bennett JP Jr, Piercey MF
> University of Virginia Health Sciences Center, Charlottesville VA 22908
> USA. <jpb8u@xxxxxxxxxxxx >
> PMID: 10223406, UI: 99237917
> <>
>
> janet paterson - 52 now /41 dx /37 onset - janet313@xxxxxxxxxxx
> 613/256/8340 - PO Box 171/Almonte/Ontario/K0A 1A0/Canada
>
> Scan some of My Past Posts at:
>      
> Mine the PD List Archives at:
>      
> Cull Nine Million Pub-Med Medical Studies at:
>      
> Comb the 'People With Parkinson's' PWP WebRing at:
>